Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV
OBJECTIVE:To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism. DESIGN:Secondary analysis of pla...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2016-07, Vol.30 (12), p.1935-1942 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1942 |
|---|---|
| container_issue | 12 |
| container_start_page | 1935 |
| container_title | AIDS (London) |
| container_volume | 30 |
| creator | Hsieh, Evelyn Fraenkel, Liana Han, Yang Xia, Weibo Insogna, Karl L Yin, Michael T Zhu, Ting Cheng, Xinqi Li, Taisheng |
| description | OBJECTIVE:To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.
DESIGN:Secondary analysis of plasma samples collected from an ongoing multicenter clinical trial.
METHODS:Plasma samples collected at 0, 24, and 48 weeks after initiation of TDF + lamivudine + efavirenz from 134 adult participants enrolled in a multicenter randomized trial were analyzed. Data regarding sociodemographic and clinical characteristics were obtained as part of the parent study. Laboratory analyses included plasma DBP, intact parathyroid hormone, total 25-hydroxy vitamin D, phosphorus, the bone resorption marker collagen type 1 cross-linked C-telopeptide, and the bone formation marker total procollagen type 1 N-terminal propeptide. Repeated measures analysis of variance was used to measure changes in biomarkers over time.
RESULTS:Our sample included 108 men and 26 women (mean age 33.6 ± 9.6 years). Median levels of DBP increased significantly from baseline to 48 weeks [154 (91.8–257.4) versus 198.3 (119.6–351.9) μg/ml, P |
| doi_str_mv | 10.1097/QAD.0000000000001131 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4949136</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1819139373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4901-54f1610082a39446c3975dc7f68e9c12642d3ed54d39c68b842270feeaa4decc3</originalsourceid><addsrcrecordid>eNqNkc9u1DAQxiMEokvhDRDykUu6duzE9gWpaguttFKFBFwtrzPZNTj2YjtZwQvw2ni1pWo5IHwZz8xvPv_5quo1wWcES778eH55hh8sQih5Ui0I47RuW06eVgvcdLKWlOOT6kVKXwvUYiGeVycNJw0TsltUv1bBb2yeeuu1Q9abCDpB2aDZZj2WeInW1pf2Bu1iyFAqDmZwCekhQyykzVZnGzwKA8rgwxBmG5euDM8HWVjCoEsF_E-kx3IaOsjNtp90EdnbvEXXN19eVs-GksOru3hafX5_9eniul7dfri5OF_VhklM6pYNpCMYi0ZTyVhnqORtb_jQCZCGNB1regp9y3oqTSfWgjUNxwOA1qwHY-hp9e6ou5vWI_QGfI7aqV20o44_VNBWPe54u1WbMCsmmSS0KwJv7wRi-D5Bymq0yYBz2kOYkiKCFK58Ov0PFLe8FS1vCsqOqIkhpQjD_Y0IVge7VbFb_W13GXvz8DX3Q3_8LYA4Avvgilvpm5v2ENUWtMvbf2v_Bvo7uhY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1805758572</pqid></control><display><type>article</type><title>Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Hsieh, Evelyn ; Fraenkel, Liana ; Han, Yang ; Xia, Weibo ; Insogna, Karl L ; Yin, Michael T ; Zhu, Ting ; Cheng, Xinqi ; Li, Taisheng</creator><creatorcontrib>Hsieh, Evelyn ; Fraenkel, Liana ; Han, Yang ; Xia, Weibo ; Insogna, Karl L ; Yin, Michael T ; Zhu, Ting ; Cheng, Xinqi ; Li, Taisheng</creatorcontrib><description>OBJECTIVE:To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.
DESIGN:Secondary analysis of plasma samples collected from an ongoing multicenter clinical trial.
METHODS:Plasma samples collected at 0, 24, and 48 weeks after initiation of TDF + lamivudine + efavirenz from 134 adult participants enrolled in a multicenter randomized trial were analyzed. Data regarding sociodemographic and clinical characteristics were obtained as part of the parent study. Laboratory analyses included plasma DBP, intact parathyroid hormone, total 25-hydroxy vitamin D, phosphorus, the bone resorption marker collagen type 1 cross-linked C-telopeptide, and the bone formation marker total procollagen type 1 N-terminal propeptide. Repeated measures analysis of variance was used to measure changes in biomarkers over time.
RESULTS:Our sample included 108 men and 26 women (mean age 33.6 ± 9.6 years). Median levels of DBP increased significantly from baseline to 48 weeks [154 (91.8–257.4) versus 198.3 (119.6–351.9) μg/ml, P < 0.001]. A concurrent rise in intact parathyroid hormone levels was observed over the same period [32.3 (24.4–40.9) versus 45.2 (35.1–60.4) pg/ml, P < 0.001]; however, 25-hydroxy vitamin D and phosphorus levels remained stable. Bone resorption and formation markers rapidly increased from 0 to 24 weeks, followed by a slight decline or plateau, but remained significantly elevated at 48 weeks (P < 0.001).
CONCLUSION:Our study provides longitudinal data supporting a potential role for DBP in bone loss associated with TDF-based therapy. Further research to elucidate the mechanistic pathways and clinical impact of these findings is warranted.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0000000000001131</identifier><identifier>PMID: 27124896</identifier><language>eng</language><publisher>England: Copyright Wolters Kluwer Health, Inc</publisher><subject>Adolescent ; Adult ; Aged ; AIDS/HIV ; Anti-HIV Agents - adverse effects ; Anti-HIV Agents - therapeutic use ; Benzoxazines - adverse effects ; Benzoxazines - therapeutic use ; Bone Resorption - chemically induced ; Female ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV Infections - pathology ; Human immunodeficiency virus ; Humans ; Lamivudine - adverse effects ; Lamivudine - therapeutic use ; Lentivirus ; Longitudinal Studies ; Male ; Middle Aged ; Plasma - chemistry ; Retroviridae ; Tenofovir - adverse effects ; Tenofovir - therapeutic use ; Vitamin D-Binding Protein - blood ; Young Adult</subject><ispartof>AIDS (London), 2016-07, Vol.30 (12), p.1935-1942</ispartof><rights>Copyright © 2016 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4901-54f1610082a39446c3975dc7f68e9c12642d3ed54d39c68b842270feeaa4decc3</citedby><cites>FETCH-LOGICAL-c4901-54f1610082a39446c3975dc7f68e9c12642d3ed54d39c68b842270feeaa4decc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27124896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hsieh, Evelyn</creatorcontrib><creatorcontrib>Fraenkel, Liana</creatorcontrib><creatorcontrib>Han, Yang</creatorcontrib><creatorcontrib>Xia, Weibo</creatorcontrib><creatorcontrib>Insogna, Karl L</creatorcontrib><creatorcontrib>Yin, Michael T</creatorcontrib><creatorcontrib>Zhu, Ting</creatorcontrib><creatorcontrib>Cheng, Xinqi</creatorcontrib><creatorcontrib>Li, Taisheng</creatorcontrib><title>Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>OBJECTIVE:To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.
DESIGN:Secondary analysis of plasma samples collected from an ongoing multicenter clinical trial.
METHODS:Plasma samples collected at 0, 24, and 48 weeks after initiation of TDF + lamivudine + efavirenz from 134 adult participants enrolled in a multicenter randomized trial were analyzed. Data regarding sociodemographic and clinical characteristics were obtained as part of the parent study. Laboratory analyses included plasma DBP, intact parathyroid hormone, total 25-hydroxy vitamin D, phosphorus, the bone resorption marker collagen type 1 cross-linked C-telopeptide, and the bone formation marker total procollagen type 1 N-terminal propeptide. Repeated measures analysis of variance was used to measure changes in biomarkers over time.
RESULTS:Our sample included 108 men and 26 women (mean age 33.6 ± 9.6 years). Median levels of DBP increased significantly from baseline to 48 weeks [154 (91.8–257.4) versus 198.3 (119.6–351.9) μg/ml, P < 0.001]. A concurrent rise in intact parathyroid hormone levels was observed over the same period [32.3 (24.4–40.9) versus 45.2 (35.1–60.4) pg/ml, P < 0.001]; however, 25-hydroxy vitamin D and phosphorus levels remained stable. Bone resorption and formation markers rapidly increased from 0 to 24 weeks, followed by a slight decline or plateau, but remained significantly elevated at 48 weeks (P < 0.001).
CONCLUSION:Our study provides longitudinal data supporting a potential role for DBP in bone loss associated with TDF-based therapy. Further research to elucidate the mechanistic pathways and clinical impact of these findings is warranted.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Benzoxazines - adverse effects</subject><subject>Benzoxazines - therapeutic use</subject><subject>Bone Resorption - chemically induced</subject><subject>Female</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - pathology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Lamivudine - adverse effects</subject><subject>Lamivudine - therapeutic use</subject><subject>Lentivirus</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Plasma - chemistry</subject><subject>Retroviridae</subject><subject>Tenofovir - adverse effects</subject><subject>Tenofovir - therapeutic use</subject><subject>Vitamin D-Binding Protein - blood</subject><subject>Young Adult</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9u1DAQxiMEokvhDRDykUu6duzE9gWpaguttFKFBFwtrzPZNTj2YjtZwQvw2ni1pWo5IHwZz8xvPv_5quo1wWcES778eH55hh8sQih5Ui0I47RuW06eVgvcdLKWlOOT6kVKXwvUYiGeVycNJw0TsltUv1bBb2yeeuu1Q9abCDpB2aDZZj2WeInW1pf2Bu1iyFAqDmZwCekhQyykzVZnGzwKA8rgwxBmG5euDM8HWVjCoEsF_E-kx3IaOsjNtp90EdnbvEXXN19eVs-GksOru3hafX5_9eniul7dfri5OF_VhklM6pYNpCMYi0ZTyVhnqORtb_jQCZCGNB1regp9y3oqTSfWgjUNxwOA1qwHY-hp9e6ou5vWI_QGfI7aqV20o44_VNBWPe54u1WbMCsmmSS0KwJv7wRi-D5Bymq0yYBz2kOYkiKCFK58Ov0PFLe8FS1vCsqOqIkhpQjD_Y0IVge7VbFb_W13GXvz8DX3Q3_8LYA4Avvgilvpm5v2ENUWtMvbf2v_Bvo7uhY</recordid><startdate>20160731</startdate><enddate>20160731</enddate><creator>Hsieh, Evelyn</creator><creator>Fraenkel, Liana</creator><creator>Han, Yang</creator><creator>Xia, Weibo</creator><creator>Insogna, Karl L</creator><creator>Yin, Michael T</creator><creator>Zhu, Ting</creator><creator>Cheng, Xinqi</creator><creator>Li, Taisheng</creator><general>Copyright Wolters Kluwer Health, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T2</scope><scope>7T5</scope><scope>7U2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20160731</creationdate><title>Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV</title><author>Hsieh, Evelyn ; Fraenkel, Liana ; Han, Yang ; Xia, Weibo ; Insogna, Karl L ; Yin, Michael T ; Zhu, Ting ; Cheng, Xinqi ; Li, Taisheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4901-54f1610082a39446c3975dc7f68e9c12642d3ed54d39c68b842270feeaa4decc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Benzoxazines - adverse effects</topic><topic>Benzoxazines - therapeutic use</topic><topic>Bone Resorption - chemically induced</topic><topic>Female</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - pathology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Lamivudine - adverse effects</topic><topic>Lamivudine - therapeutic use</topic><topic>Lentivirus</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Plasma - chemistry</topic><topic>Retroviridae</topic><topic>Tenofovir - adverse effects</topic><topic>Tenofovir - therapeutic use</topic><topic>Vitamin D-Binding Protein - blood</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hsieh, Evelyn</creatorcontrib><creatorcontrib>Fraenkel, Liana</creatorcontrib><creatorcontrib>Han, Yang</creatorcontrib><creatorcontrib>Xia, Weibo</creatorcontrib><creatorcontrib>Insogna, Karl L</creatorcontrib><creatorcontrib>Yin, Michael T</creatorcontrib><creatorcontrib>Zhu, Ting</creatorcontrib><creatorcontrib>Cheng, Xinqi</creatorcontrib><creatorcontrib>Li, Taisheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Safety Science and Risk</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hsieh, Evelyn</au><au>Fraenkel, Liana</au><au>Han, Yang</au><au>Xia, Weibo</au><au>Insogna, Karl L</au><au>Yin, Michael T</au><au>Zhu, Ting</au><au>Cheng, Xinqi</au><au>Li, Taisheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2016-07-31</date><risdate>2016</risdate><volume>30</volume><issue>12</issue><spage>1935</spage><epage>1942</epage><pages>1935-1942</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>OBJECTIVE:To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.
DESIGN:Secondary analysis of plasma samples collected from an ongoing multicenter clinical trial.
METHODS:Plasma samples collected at 0, 24, and 48 weeks after initiation of TDF + lamivudine + efavirenz from 134 adult participants enrolled in a multicenter randomized trial were analyzed. Data regarding sociodemographic and clinical characteristics were obtained as part of the parent study. Laboratory analyses included plasma DBP, intact parathyroid hormone, total 25-hydroxy vitamin D, phosphorus, the bone resorption marker collagen type 1 cross-linked C-telopeptide, and the bone formation marker total procollagen type 1 N-terminal propeptide. Repeated measures analysis of variance was used to measure changes in biomarkers over time.
RESULTS:Our sample included 108 men and 26 women (mean age 33.6 ± 9.6 years). Median levels of DBP increased significantly from baseline to 48 weeks [154 (91.8–257.4) versus 198.3 (119.6–351.9) μg/ml, P < 0.001]. A concurrent rise in intact parathyroid hormone levels was observed over the same period [32.3 (24.4–40.9) versus 45.2 (35.1–60.4) pg/ml, P < 0.001]; however, 25-hydroxy vitamin D and phosphorus levels remained stable. Bone resorption and formation markers rapidly increased from 0 to 24 weeks, followed by a slight decline or plateau, but remained significantly elevated at 48 weeks (P < 0.001).
CONCLUSION:Our study provides longitudinal data supporting a potential role for DBP in bone loss associated with TDF-based therapy. Further research to elucidate the mechanistic pathways and clinical impact of these findings is warranted.</abstract><cop>England</cop><pub>Copyright Wolters Kluwer Health, Inc</pub><pmid>27124896</pmid><doi>10.1097/QAD.0000000000001131</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2016-07, Vol.30 (12), p.1935-1942 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4949136 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Adolescent Adult Aged AIDS/HIV Anti-HIV Agents - adverse effects Anti-HIV Agents - therapeutic use Benzoxazines - adverse effects Benzoxazines - therapeutic use Bone Resorption - chemically induced Female HIV Infections - complications HIV Infections - drug therapy HIV Infections - pathology Human immunodeficiency virus Humans Lamivudine - adverse effects Lamivudine - therapeutic use Lentivirus Longitudinal Studies Male Middle Aged Plasma - chemistry Retroviridae Tenofovir - adverse effects Tenofovir - therapeutic use Vitamin D-Binding Protein - blood Young Adult |
| title | Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A16%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20increase%20in%20vitamin%20D%20binding%20protein%20levels%20after%20initiation%20of%20tenofovir/lamivudine/efavirenz%20among%20individuals%20with%20HIV&rft.jtitle=AIDS%20(London)&rft.au=Hsieh,%20Evelyn&rft.date=2016-07-31&rft.volume=30&rft.issue=12&rft.spage=1935&rft.epage=1942&rft.pages=1935-1942&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0000000000001131&rft_dat=%3Cproquest_pubme%3E1819139373%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1805758572&rft_id=info:pmid/27124896&rfr_iscdi=true |